Results 241 to 250 of about 122,299 (353)

Underlying disease is the main risk factor in post‐splenectomy complication risk: Data from a national database

open access: yesBritish Journal of Haematology, Volume 206, Issue 6, Page 1811-1821, June 2025.
The association between underlying haematological disease, age at splenectomy and post‐splenectomy complications was explored among 1348 splenectomized patients, followed in 53 clinical centres with a median follow‐up time of 13 years and affected by transfusion‐dependent thalassaemia (TDT), non‐transfusion‐dependent thalassaemia (NTDT), sickle cell ...
Maddalena Casale   +44 more
wiley   +1 more source

How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome

open access: yesBritish Journal of Haematology, EarlyView.
Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley   +1 more source

Home - About - Disclaimer - Privacy